A Novel Role of Alpha Lipoic Acid in Comparison With Selenium in Mitochondrial Resuscitation and miRNA-126 Expression in Hemodialysis Patients
Phase 4
Completed
- Conditions
- Antioxidative StressEnd Stage Renal Disease on Dialysis
- Interventions
- Registration Number
- NCT05266794
- Lead Sponsor
- Ain Shams University
- Brief Summary
An Open labeled, Paralled, Randomized, Prospective, study was conducted on 60 patients who were randomized into 3 groups, 22, 20 and 18 patients in Control, Selenium and, Thiotacid groups respectively. Serum levels of ROS, CoQ10, and miRNA-126 were assessed at base line and after three months for all patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 68
Inclusion Criteria
- prevalent hemodialysis patients
Exclusion Criteria
- Patients with Inflammatory diseases, hepatic or respiratory diseases, smokers and alcoholics, were excluded from the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Alpha Lipoic acid Alpha lipoic acid 20 hemodialysispatients who received Alpha Lipoic acid (ALA) (Thiotex fort®) 600mg once daily with their routine therapy just after the dialysis sessions for 3 months. Selenium Selenium 23 hemodialysis patients who received Selenium 200µg once daily with their routine therapy just after the dialysis sessions for 3 months.
- Primary Outcome Measures
Name Time Method Change in miRNA-126 level 3 months Fold expression
Change in Co Q10 level (ng/ml) 3 months Using ELISA kit
Change ROS level (ng/ml) 3 months Using ELISA kit
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Ain Shams University
🇪🇬Cairo, Egypt